Jpmorgan Chase & CO Neuro Pace Inc Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Neuro Pace Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 11,997 shares of NPCE stock, worth $134,246. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,997
Previous 5,816
106.28%
Holding current value
$134,246
Previous $43,000
93.02%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding NPCE
# of Institutions
52Shares Held
21.3MCall Options Held
1.3KPut Options Held
100-
Kck Ltd. Tortola, D85.62MShares$62.9 Million77.74% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.41MShares$38.1 Million0.56% of portfolio
-
Morgan Stanley New York, NY2.49MShares$27.9 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.43MShares$27.2 Million1.44% of portfolio
-
Kent Lake Pr LLC Anasco, PR1.25MShares$14 Million3.46% of portfolio
About NeuroPace Inc
- Ticker NPCE
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 24,846,900
- Market Cap $278M
- Description
- NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...